GlassScriptPhysician profile
Kennedy K Lim
NPI 1801825211
$8,156.80
in general payments reported to CMS, 2019-2025
46 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $952 · 2021: $1,553 · 2022: $982 · 2023: $1,483 · 2024: $854 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,123.42 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $848.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $653.69 | 2019-2025 | |
| Novo Nordisk INC | $591.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $581.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $563.65 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Esperion Therapeutics, INC. | $370.24 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $283.59 | 2019-2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $257.35 | 2019-2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $235.95 | 2021-2025 | |
| Amarin Pharma, INC. | $204.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $189.41 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $168.10 | 2019-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $165.19 | 2021-2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.50 | 2020-2024 | Xifaxan |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148.85 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $137.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.12 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $125.00 | 2023 | Rebyota |
| Shionogi INC | $125.00 | 2023 | Fetroja |
| Sanofi-Aventis U.S. LLC | $117.45 | 2019-2022 | |
| Mylan Specialty L.P. | $100.35 | 2021-2023 | Yupelri |
| Dexcom, INC. | $87.50 | 2024-2025 | Dexcom G6 Transmitter |
| Aurinia Pharma U.S., INC. | $85.93 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $70.88 | 2019-2024 | |
| Allergan, INC. | $67.64 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.28 | 2022 | |
| Avanir Pharmaceuticals, INC. | $49.83 | 2019 | |
| Shield Therapeutics INC | $46.24 | 2025 | |
| Ibsa Pharma INC. | $40.43 | 2021-2025 | Licart, Flector, Tirosint |
| Corcept Therapeutics | $38.83 | 2023-2025 | Korlym |
| Inogen, INC. | $34.01 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Intuitive Surgical, INC. | $33.44 | 2019 | |
| Itamar Medical INC | $30.57 | 2024 | Watchpatone |
| Pharmacyclics LLC, An Abbvie Company | $24.34 | 2023 | Epkinly |
| Nevro Corp. | $24.26 | 2022 | |
| Organogenesis INC. | $22.42 | 2023 | Puraply |
| Vifor Pharma, INC. | $22.01 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.37 | 2024 | Keveyis |
| Exact Sciences Corporation | $21.07 | 2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $20.83 | 2019 | |
| Abiomed | $20.37 | 2025 | |
| Sumitomo Pharma America, INC. | $17.75 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.51 | 2023 | Quviviq |
| Viatris Specialty LLC | $15.51 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kennedy Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.